Cleerly is making the future of cardiovascular care possible through easy-to-use, clinically proven technology that effortlessly integrates into provider workflows and patient care journeys.
Our personalized care pathway for heart attack prevention creates value for health plans through healthier and happier patients, more efficient providers, and reduced waste for the healthcare system.
Benefits to health plans
Empowered providers can manage true heart disease risk
Fast, accurate disease phenotyping is critical in early identification, characterization, and treatment of a patient’s coronary artery disease (CAD). For this information to be most useful, however, it must be readily available and informative to providers.
Cleerly’s precision heart care approach emphasizes clear interpretation of coronary computed tomography angiogram (CCTA) results for each stakeholder. Color-coded images effortlessly depict the exact location, type and volume of plaque that is present and makes it easily understandable by both the provider and the patient. The degree of vessel narrowing is also clearly presented and understandable by all stakeholders, including the physician interpreting the exam, the treating provider and the patient. This approach can align all of the stakeholders in the care pathway.
Cleerly pairs these images with an assessment of plaque volume using the newly described CAD Staging System.1 Physicians use staging systems to determine a patient’s prognosis and to determine a treatment plan; these are widely used for cancer and many other common chronic conditions. Until recently a staging system for heart disease was notably absent from this list, in large part because the current standard of cardiovascular care lacked a reliable way to measure the volume and address the progression of coronary artery disease.
The combination of easy-to-understand CCTA scan results and a first-of-its-kind staging system for cardiovascular disease severity empowers providers to make more informed treatment and personalized care plan decisions.
Tailored treatment improves patient experience
All efforts to improve care delivery must consider the perspective of the patient, from how they are impacted to inconsistencies, inefficiencies, and delays in care delivery to whether treatment options align with their personal health and well-being goals.
It’s often a cliché to say that patients are at the center of value-based care, but Cleerly fundamentally believes this is the case with its precision heart care approach. Numerous studies, including a recent analysis of the prospective multicenter randomized controlled CONSERVE trial, support AI-enabled CCTA for accurate detection of CAD and a means to reduce unnecessary and expensive invasive procedures, and supports enhanced prevention strategies that benefit patients and providers alike2.
That’s why Cleerly focuses its precision heart care model on accuracy and non-invasive testing with easy-to-interpret results. Patients are able to receive the right level of care based not on risk factors and other surrogate markers but also on their true risk, the presence of non-calcified plaque3, and can work with their provider on a personalized treatment plan.
Value creation by eliminating unnecessary procedures
Cleerly precision heart care allows for a more proactive and preventive approach to cardiovascular care, as treatment options for lower-level stages may include lifestyle changes or medications as opposed to unnecessary therapies or expensive, invasive procedures. Expanded use of CCTA provides a strong line of defense against high-cost, low-value utilization procedures that may cause patient harm. With nearly two-thirds of invasive angiographies shown to be unnecessary, Cleerly can help reduce waste for the healthcare system through avoidance of these procedures.
The business of healthcare today emphasizes quality care that drives clinical and economic improvements, as well as patient and provider experience. Cleerly advances these goals by enabling providers to personalize treatment. Download our report, Precision heart care’s role in supporting the business of healthcare, to learn more about the benefits of Cleerly for your member populations.
LEARN MORE IN OUR LATEST REPORT
References:
1. (Min et al JCCT 2022)
2. Kim Y, Choi AD, et al. AI-QCT: Gatekeeper for Invasive Angiography? CONSERVE Sub- Study. Journal of Cardiovascular CT. Vol 16, Issue 4, Supplement S6-S7, July 01, 2022.
3. The Relationship Between Coronary Calcification and the Natural History of Coronary Artery Disease. Journal of the American College of Cardiology Cardiovascular Imaging. January 2021.
Cleerly
Cleerly : January 17, 2023
